Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

OncoGenex Pharmaceuticals Inc (NASDAQ:OGXI)

2.75
Delayed Data
As of Sep 04
 -0.31 / -10.13%
Today’s Change
1.38
Today|||52-Week Range
4.10
+20.09%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$91.2M

Company Description

OncoGenex Pharmaceuticals, Inc. is a biopharmaceutical company. It develops and commercializes new cancer therapies that address treatment resistance in cancer patients. It has developed a pipeline of late-stage product candidates that are designed to block the production of specific proteins that promote treatment resistance in cancer. The company operates through three product pipeline: custirsen, apatorsen and OGX-225. OncoGenex Pharmaceuticals was founded by Martin E. Gleave and Scott Daniel Cormack in October 1991 and is headquartered in Bothell, WA.

Contact Information

OncoGenex Pharmaceuticals, Inc.
19820 North Creek Parkway
Bothell Washington 98011
P:(425) 686-1500
Investor Relations:
(425) 686-1514

Employees

Shareholders

Mutual fund holders--
Individual stakeholders--
Other institutional--

Top Executives

Scott Daniel CormackPresident, CEO, Secretary, Treasurer & Director
John A. BencichChief Financial Officer & Vice President
Patricia S. StewartVice President-Clinical Development
Cindy A. JacobsChief Medical Officer & Executive Vice President
Jaime WelchVP-Marketing & Corporate Communications